Leukemia, Myeloid, Acute
Conditions
Keywords
Acute myelogenous leukemia, Allogenetic stem cell transplant, Maintenance therapy, Azacitidine, Chidamide, High-risk AML
Brief summary
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
Detailed description
The Study Drug: Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better. Chidamide exhibits potent inhibitory effect on cell viability of MDS and AML cells, and the possible mechanism may lie in the downregulation of JAK2/STAT3 signaling through SOCS3 upregulation. Study Group： If you are found to be eligible to take part in this study,you will receive azacitidine and chidamide. Study Drug Administration: You will recieve six courses of azacitidine through a needle under your skin on Days 1-3.Each course is 28 days long.At the same time you will recieve oral chidamide per day for no more than 2 years. The treatment will start after 30 days post-transplantation and your neutrophil count is of 1.5 × 10⁹ cells per L or higher and non-transfused platelets is of 80 × 10⁹ per L or higher. The treatment would stop if neutrophil count is less than 0.5 × 10⁹ cells per L or platelets is less than 50 × 10⁹ per L.And it would also stop when grade 3/4 non-hematological adverse events happened. Study Visit: You may come back for study visits every month in a year when the treatment start. Blood and urine will be drawn for routine tests every month. At 1,2,3,4,5,6,9 and 12 months,You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. Length of Study: You will be on study treatment for up to 1 year.You will be taken off study early if you experience intolerable side effects or the disease gets worse. End-of-Treatment Visit: If you complete the planned treatment with azacitidine and chidamide, you will have an end-of-treatment visit: Blood and urine will be drawn for routine tests. You will have a bone marrow aspiration to check the status of the disease. You will have a electrocardiiogram test every 3 months to check the heart function. This is an investigational study. Azacitidine and chidamide are FDA approved and are commercially available for the treatment of acute leukemia.
Interventions
DRUGAzacitidine
Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.
DRUGChidamide
Patients will recieve oral chidamide 5mg per day for no more than 2 years.
Sponsors
Zhujiang Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 1.Age 18 to 60 years old,both male and female * 2.Be able to understand and sign informed consent * 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic * 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML * 5.Patients with an ECOG performance status 0,1,2 or 3 * 6.Expected survival time ≥ 3 months * 7.Non-hematological toxicity related to transplantation does not exceed Grade 2 * 8.Laboratory indicators meet the following standards: 1. 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal. 2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10/L and without G-CSF treatment. 3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10/L and without platelet transfusion. 4. Serum creatinine clearance rate is greater than 30ml/min.
Exclusion criteria
* 1.Uncontrollable active infection * 2.Patients with active hepatitis B or C or HIV infection before enrollment * 3.Have a grade III-IV graft-versus-host disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Paticipants With Adverse Events as a Measure of Safety | From the day of stem cell transplantation to one year after stem cell transplantation | Safety were measured with respect to: 1. Safety measurements 2. Incidence of adverse events |
| One year cumulative incidence of relapse | From the day of stem cell transplantation to one year after stem cell transplantation | Leukemia relapse base on morphoogy criterion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapes-free Survival（RFS） | From the day of stem cell transplantation to one year after stem cell transplantation | The time that a participant survives without relapes of the disease |
| Overall survival（OS） | From the day of stem cell transplantation to one year after stem cell transplantation | The time that a participant survives without death |
| The cumulative Incidence rate of GVHD | From the day of stem cell transplantation to one year after stem cell transplantation | acute GVHD and chronic GVHD diagnosis based on MIH criterion |
Countries
China
Contacts
CONTACTRui Huang, Doctor
CONTACTYunqing Wang, Bachelor
PRINCIPAL_INVESTIGATORRui Huang, Doctor
Zhujiang Hospital
Outcome results
None listed